Table 1.
Characteristics of preformed DSA‐positive patients who underwent LDLT between July 1997 and January 2016, in Hokkaido University Hospital
| DSA‐negative (n = 123) | “DSA‐positive” (n = 41) | p | |||
|---|---|---|---|---|---|
| FCXM‐positive (n = 27) | LCT‐positive (n = 14) | ||||
| Sex, female, # (%) | Recipient | 49 (39.8) | 19 (70.4) | **14 (100.0) | **0.001 versus non‐DSA |
| Donor | 43 (35.0) | 9 (33.3) | 3 (21.4) | 0.66 | |
| Age | Recipient | 50.3 ± 11.6 | 54.1 ± 8.8 | *50.5 ± 5.3 | *<0.05 versus FCXM+ |
| Donor | 35.8 ± 11.1 | 36.7 ± 14.0 | 41.1 ± 13.0 | 0.74 | |
| Liver disease etiology, # (%) | 0.23 | ||||
| HCV/HBV/HCC | 23(18.7)/31(25.2)/9(7.3) | 3(11.1)/3(11.1)/2(7.4) | 1(7.1)/1(7.1)/1(7.1) | PBC or not | |
| EtOH/PBC/PSC | 7(5.7)/15(12.2)/4(3.3) | 3(11.1)/7(25.9)/2(7.4) | 1(7.1)/**6(42.9)/0(0) | **0.0025 versus non‐DSA | |
| Fulminant/AIH/cryptogenic | 16(13.0)/3(2.4)/2(1.6) | 1(3.7)/2(7.4)/0(0) | 2(14.3)/0(0)/2(14.3) | ||
| NASH/ADPKD/Others | 4(3.3)/3(2.4)/7(5.7) | 1(3.7)/2(7.4)/1(3.7) | 0(0)/0(0)/0(0) | ||
| Pre‐LT status | |||||
| Outpts/Hospital/ICU, # (%) | 52(42.3)/50(40.7)/21(17.1) | 6(22.2)/17(63.0)/4(14.8) | 6(42.9)/4(28.6)/4(28.6) | 0.15 | |
| Pre‐LT hospital days | 19.3 ± 23.8 | 27.4 ± 31.6 | #11.6 ± 14.2 | #0.08 versus FCXM + | |
| MELD | 17.5 ± 10.3 | 18.8 ± 10.1 | 19.0 ± 10.6 | 0.91 | |
| CTP A/B/C, # (%) | 15(12.6)/38(31.9)/67(55.4) | 3(11.1)/6(22.2)/18(66.7) | 1(7.1)/3(21.4)/9(64.3) | 0.59 | |
| Height (cm) | Recipient | 163.8 ± 10.2 | **156.9 ± 8.1 | **153.7 ± 3.8 | **<0.0015 versus non‐DSA |
| Donor | 166.7 ± 8.6 | 164.2 ± 6.7 | 163.7 ± 5.6 | 0.87 | |
| Weight (kg) | Recipient | 61.7 ± 10.8 | *57.3 ± 9.1 | 57.3 ± 11.4 | *<0.05 versus non‐DSA |
| Donor | 63.0 ± 12.3 | 59.1 ± 10.0 | 62.9 ± 7.4 | 1.0 | |
| BSA (m2) | Recipient | 1.67 ± 0.18 | **1.56 ± 0.18 | **1.54 ± 0.10 | **<0.005 versus non‐DSA |
| BMI | Recipient | 23.0 ± 3.3 | 23.2 ± 3.2 | 24.3 ± 4.1 | 1.3 |
| Donor | 22.6 ± 3.4 | 21.9 ± 3.3 | 23.6 ± 3.1 | 0.42 | |
| SV (ml) | 1179.0 ± 128.1 | *1107.2 ± 126.2 | *1090.2 ± 73.3 | *<0.05 versus non‐DSA | |
| Graft Left/Right, # (%) | 75 (61.0)/48 (39.0) | 13 (48.2)/14 (51.9) | 8 (57.1)/6 (42.9) | 0.47 | |
| GV, ml | 465.1 ± 133.5 | 472.9 ± 126.7 | 485.4 ± 173.8 | 0.95 | |
| GV/SV, % | 39.4 ± 10.3 | 42.8 ± 10.9 | 45.0 ± 18.0 | 0.82 | |
| Relation to donor, # (%) | |||||
| Parents/Spouse/Siblings Offspring/Others | 8(6.5)/24(19.5)/20(16.3) | 0(0)/6(22.2)/2(7.4) | 0(0)/7(50.0)/1(7.1) | 0.11 | |
| 65(52.9)/6(4.9) | 17(63.0)/2(7.4) | 6(42.9)/0(0) | |||
| Operation time, min | 1034.6 ± 237.0 | #939.2 ± 117.8 | 1140.1 ± 318.4 | #0.065 versus non‐DSA | |
| CIT, min | 71.4 ± 38.9 | 94.0 ± 91.6 | **50.9 ± 40.9 | **<0.005 versus others | |
| WIT, min | 49.0 ± 15.9 | 43.9 ± 10.9 | 52.4 ± 15.9 | 0.10 | |
| Blood loss in LT, g | 8401.8 ± 8790.8 | 6332.8 ± 4350.9 | #10248.2 ± 7093.3 | #0.071 versus FCXM + | |
| Splenectomy, # (%) | 38 (30.9) | 9 (33.3) | 2 (14.3) | 0.39 | |
Note: Mann–Whitney U‐test or Fisher's exact test. Data are shown as mean ± standard deviation, except where indicated otherwise. #<0.1; *<0.05; **<0.005; ***<0.0001.
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; AIH, autoimmune hepatitis; CIT, cold ischemia time; CTP, Child–Turcotte–Pugh; DSA, donor‐specific antibody; EtOH, alcoholic cirrhosis; FCXM, flowcytometric crossmatch test; GV/SV, graft volume to standard liver volume; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; LCT, lymphocyte cytotoxicity test; MELD, Model for End‐stage Liver Disease; NASH, nonalcoholic steatohepatitis; LT, liver transplant; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; WIT, warm ischemia time.